PG 102 - ViroMed

Drug Profile

PG 102 - ViroMed

Alternative Names: PG102-ViroMed

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer SBI Biotech; ViroMed
  • Class Plant allergy immunotherapies
  • Mechanism of Action Helper-inducer T-lymphocyte inhibitors; IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic contact dermatitis
  • Preclinical Allergic rhinitis

Most Recent Events

  • 17 Jun 2015 PG 102 is still in phase-II development for Allergic diseases in South Korea
  • 17 Jun 2010 Phase-II clinical trials in Allergic contact dermatitis in South Korea (unspecified route)
  • 17 Jun 2010 Preclinical trials in Allergic rhinitis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top